Glenmark Pharma gets USFDA nod for generic version of Nexium to treat acid reflux
The approved products Esomeprazole Magnesium delayed-release capsule is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.
New Delhi: Glenmark Pharmaceuticals on May 14 said it has received final approval from the US health regulator for a generic version of AstraZeneca's Nexium, used to treat acid reflux.
Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Esomeprazole Magnesium delayed-release capsules USP in the strengths of 20 mg and 40 mg, the company said in a BSE filing.
The approved products is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.
Also Read: Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd